T-CELL PROLYMPHOCYTIC LEUKEMIA
Clinical trials for T-CELL PROLYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL PROLYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to keep cancer at bay after risky transplant
Disease control Recruiting nowThis study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study aims to find a safe and effective dose of two drugs, ruxolitinib and duvelisib, for adults whose T-cell or NK-cell lymphoma has returned or not responded to prior treatments. The main goal is to determine the highest dose patients can tolerate without sever…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC